Key result
Mitral valve replacement with cardiopulmonary bypass at 17 weeks gestation links to adverse neurological sequelae.
Why the study?
What are the fetomaternal outcomes of cardiopulmonary bypass and mitral valve replacement during pregnancy?
Case Report (n=1)
What are the fetomaternal outcomes of cardiopulmonary bypass and mitral valve replacement during pregnancy?
Cardiopulmonary bypass during pregnancy carries a maternal mortality similar to nonpregnant females but is associated with a high fetal mortality of 16-33%.
Answers are grounded in this paper and cite their sources.
Neurological sequelae after bypass-supported mitral valve replacement in mid-pregnancy signal caution; leaves open optimal timing and neuroprotection strategies.
Gravid patient cardiopulmonary bypass remains a high-risk procedure with regard to fetal preservation. Maternal mortality is similar to that of the nonpregnant female at 1.5-5%. However, fetal mortality remains high at 16-33%, with an average of 19% over the past 25 years, with no correlation to gestational age. Teratogenesis is a major consideration in the first trimester. Variations in the timing of surgical intervention, gestational age, maternal health status, type of procedure, pre- or postorganogenesis, perfusion protocol, and pharmaceutical therapy are all factors that can influence fetomaternal outcome. In this report, we present a literature review along with our experience of a 26-year-old female who developed complications with her pregnancy at approximately 17 weeks gestation, with adverse neurological sequelae. The patient was 152 cm in height and weighed 48 kg, with a calculated body surface area of 1.40 M2. She had no prior history of cardiac disease and, upon admission to our institution, presented with a declining health status in pulmonary edema and was treated medically, with an ultimate requirement for mitral valve replacement. The total cardiopulmonary bypass time was 99 min with an aortic crossclamp time of 83 min. The literature, as expected, is limited to case reports and reviews since a controlled clinical trial during pregnancy is nonexistent, using extracorporeal circulation. This greatly challenges the medical staff in managing such difficult cases, with an incidence of heart disease during pregnancy of 1.2-3.7%.
No takes yet. Share an insight, caveat, or question.
Sutton et al. (2005) conducted a case report in Heart disease during pregnancy requiring mitral valve replacement (n=1). Cardiopulmonary bypass and mitral valve replacement was evaluated. Mitral valve replacement using cardiopulmonary bypass was performed in a 26-year-old pregnant woman at 17 weeks gestation who developed adverse neurological sequelae.
Synapse has enriched 10 related papers. Consider them for comparative context: